Biological Formulations and Methods for Treating Cardiac Tissue and Disorders
AssigneeCorMatrix Cardiovascular, Inc.
InventorRobert G. Matheny
Life of this patent
Estimating the term…
Abstract
Methods for treating damaged cardiac tissue by delivering biological formulations proximate the pericardial space of a mammalian heart that (i) enhance and supplement the properties provided by the GATA6+ macrophages in the serous fluid and/or (ii) restore, enhance and supplement the properties provided by the GATA6+ macrophages when the pericardial space is breached and the serous fluid is expelled.
Claims24
A method for treating damaged cardiac tissue, comprising:
- providing a biological formulation comprising Wharton's jelly from a mammalian source,
- said biological formulation being adapted to induce recruitment and proliferation of endogenous GATA6+ macrophages, when said biological formulation is delivered to a target site disposed in a pericardial space of a subject's heart, said pericardial space comprising serous fluid,
- delivering said biological formulation to said target site in said subject's heart, said target site also being disposed proximate a damaged tissue region,
- wherein, after said delivery of said biological formulation to said target site, said biological formulation induces recruitment and proliferation of first endogenous GATA6+ macrophages disposed proximate said damaged tissue site, whereby said biological formulation induces modulated healing of damaged tissue in said damaged tissue region.
A method for treating damaged cardiac tissue, comprising:
- providing an exosome augmented biological formulation comprising Wharton's jelly from a mammalian source and a plurality of exogenous exosomes,
- said exosome augmented biological formulation being adapted to induce recruitment and proliferation of endogenous GATA6+ macrophages contained in serous fluid and modulate at least one paracrine process associated with said GATA6+ macrophages, when said exosome augmented biological formulation is delivered to a target site disposed in a pericardial space of a subject's heart, said pericardial space comprising serous fluid,
- delivering said exosome augmented biological formulation to said target site in said subject's heart, said target site also being disposed proximate a damaged tissue region,
- wherein, after said delivery of said exosome augmented biological formulation to said target site, said exosome augmented biological formulation induces recruitment and proliferation of first endogenous GATA6+ macrophages disposed proximate said damaged tissue site and modulates at least a first paracrine process associated with said GATA6+ macrophages, whereby said exosome augmented biological formulation induces modulated healing of damaged tissue in said damaged tissue region.
The method of claim 23, wherein said cytokine comprises an interleukin selected from the group consisting of interleukin-10 (IL-10), interleukin-1α (IL-1α) and interleukin-8 (IL-8)
Dependencies are inferred from the claim text.